Alameda-based Penumbra, Inc [1]., the world’s leading thrombectomy company, has announced the promotion of Shruthi Narayan to company president. She assumes the role today, September 1.
[2]“Shruthi is a dynamic, seasoned leader whose passion for innovation and proven ability to inspire global teams make her the obvious choice for this critical role,” said Adam Elsesser, who served as president present prior to Narayan’s promotion and will now continue in his roles as chairman of the board and chief executive officer. “Her vision and focus on excellence will undoubtedly help sustain Penumbra’s exceptional growth and market leadership, expanding access to our life-saving technology to patients around the world.”
A 20-year veteran in the medical device industry, Narayan began her career at Medtronic in 2006, working in engineering, regulatory affairs and then in the cardiovascular sales organization. She joined Penumbra in 2013 as a product manager, initially working with the stroke franchise before transitioning to help build the peripheral vascular division, which commercialized the company’s global vascular portfolio of embolization and thrombectomy products.
Narayan most recently served as president of Penumbra’s interventional business where she led day-to-day operations and oversaw the growth initiatives of the company’s neuro and vascular franchises.
“Penumbra has been at the forefront of blood clot care for more than 20 years, advancing the most innovative technologies to address conditions from head-to-toe like stroke and pulmonary embolism,” Narayan said. “I am honored to carry on and expand our legacy of innovation and look forward to continuing this paradigm shift in patient care.”
The new Penumbra president’s educational background includes earning a B.S. in Electrical Engineering from Anna University in India and an M.S. in Biomedical Engineering from the University of Southern California, with a focus on Medical Device Commercialization.
Penumbra is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. The company’s portfolio, which includes computer assisted vacuum thrombectomy, centers on removing blood clots from head to toe with speed, safety, and simplicity. These innovations support healthcare providers, hospitals, and clinics in more than 100 countries, improving patient outcomes and quality of life.